ESR1 and breast carcinoma: One study in metastatic breast cancer reported improved survival only in HER2pos breast cancer patients, whereas a meta-analysis showed a survival benefit in active patients with estrogen receptor (ER)-positive breast cancer, but not in ER-negative breast cancer [9, 16].